Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Core Viewpoint - Quipt Home Medical Corp. reported strong financial results for Q4 and fiscal year 2025, highlighting organic growth and operational resilience despite industry challenges [5][6]. Financial Highlights - Q4 2025 revenue was $68.3 million, an 11% increase from $61.3 million in Q4 2024, with a sequential organic growth of 5% from Q3 2025 [6]. - Recurring revenue constituted 80% of total revenue in Q4 2025, driven by the resupply platform [6]. - Adjusted EBITDA for Q4 2025 was $14.9 million (21.8% of revenues), up from $13.4 million (21.9% of revenues) in Q4 2024, marking an 11% increase [6]. - Fiscal year 2025 revenue was $245.4 million, slightly down from $245.9 million in fiscal year 2024 [6]. - Adjusted EBITDA for fiscal year 2025 was $55.9 million (22.8% of revenue), compared to $57.7 million (23.5% of revenue) in fiscal year 2024, representing a 3% decrease [6]. - Net loss for Q4 2025 was ($3.6) million, or ($0.08) per diluted share, compared to a loss of ($2.9) million, or ($0.07) per diluted share in Q4 2024 [6]. - Net loss for fiscal year 2025 was ($10.7) million, or ($0.24) per diluted share, compared to ($6.8) million, or ($0.16) per diluted share in fiscal year 2024 [6]. - Cash flow from operating activities was $37.7 million for the year ended September 30, 2025, up from $35.4 million for the year ended September 30, 2024 [6]. - The company had $12.9 million in cash on hand as of September 30, 2025, compared to $11.3 million as of June 30, 2025 [6]. - The Net Debt to Adjusted EBITDA Leverage Ratio was 1.8x, indicating a conservative balance sheet [6][14]. Operational Highlights - The customer base increased by 10% year over year, serving 346,000 unique patients in fiscal year 2025 compared to 314,000 in fiscal year 2024 [6]. - Unique set-ups/deliveries rose to 917,000 in fiscal year 2025, a 7% increase from 854,000 in fiscal year 2024 [6]. - Respiratory resupply set-ups/deliveries increased by 1% to 486,000 in fiscal year 2025 from 480,000 in fiscal year 2024, attributed to technology and centralized intake processes [6].